|Bid||101.15 x 0|
|Ask||101.19 x 0|
|Day's Range||93.01 - 104.02|
|52 Week Range||28.80 - 104.02|
|Beta (5Y Monthly)||-0.49|
|PE Ratio (TTM)||151.24|
|Earnings Date||Aug 10, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||0.12 (0.13%)|
|Ex-Dividend Date||Apr 15, 2021|
|1y Target Est||10.00|
On April 16, 2021, Suzhou Porton Biologics Ltd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round, which raised 400 million RMB. The participants of the financing include industry's top-tier investment institutions, SDIC and GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture.
On November 1, the Opening Ceremony of Porton Biologics Gene and Cell Therapy CDMO Platform was held in Suzhou, China.